Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • Amarin Announces Additional Data From Clinical Trials 9 comments
    Apr 8, 2013 9:10 AM | about stocks: AMRN

    The data announced today further supports success of Reduce-It and should provide 100% confidence that Anchor will go through with no outcomes needed. This data also will be very sound evidence for pharma companies interested in Amarin to combine with statins, that they should act now.

    Reiterate the high side of my PT - $32.

    Stocks: AMRN
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (9)
Track new comments
  • mdenadai
    , contributor
    Comments (5) | Send Message
    I think you meant to say "100% confidence that Anchor ..."
    8 Apr 2013, 10:15 AM Reply Like
  • Pirateescapee
    , contributor
    Comments (111) | Send Message
    It would seem to me that given the complexities involved in a partnership deal that BP would want to get the ball rolling sooner than later. However Amarin's meeting with JP Morgan has them seeing any collaboration occurring around the Dec PDUFA date or perhaps even later. I can only hope that Amarin is playing possum or "hard to get" here. This share price leaves shareholders vulnerable should NCE not come through. The shorts are having a field day with this. I've held a substantial amount of shares since before the MARINE trial results. There will have to be some positive movement in the share price and institutional support soon to continue the commitment. Time is money for everyone.
    8 Apr 2013, 10:20 PM Reply Like
  • mowadeeb1
    , contributor
    Comments (11) | Send Message
    Steve, JPM out with a note today saying they do not see a buy out this year. Are you still firm in your belief of a buy out "near term"? The action in this stock is just horrible and screams a vote of no confidence in management.
    8 Apr 2013, 10:21 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (765) | Send Message
    Author’s reply » Hi, first JPM did not say no buyout/partnership this year, they said not likely until closer to or after Anchor approval. I have alluded to this ever since I blew the call that big pharma would get in prior to anchor sNDA last year. It's all about anchor now, nothing new.


    I do however believe it will occur much earlier. I have been observing reports of PFE and AZN making consulting requests for expert matter in the cardiovascular space. While it could be unrelated, I tend to believe some formal due diligence may be underway with Amarin. Just something to watch...
    9 Apr 2013, 08:52 AM Reply Like
  • chunk713
    , contributor
    Comments (41) | Send Message
    Hi Steve
    Nice info and observation. Thanks. Pay no attention to mowadeeb as he is a known basher of Amarin. Will say anything to drive the stock down or give people the wrong impression with BAD info. Keep up the great DD!
    9 Apr 2013, 11:47 AM Reply Like
  • Pirateescapee
    , contributor
    Comments (111) | Send Message
    Steve - I appreciate all your commentary, articles, research and due diligence. It is the sole reason I'm here and read what you write. Having said that, some of your language is hints that you are guessing which isn't much more than the rest of us. " I have been observing reports....." What does that mean? Is that 1st,2nd,3rd or 4th hand knowledge? "I TEND to believe some formal due diligence MAY be underway...." ?


    This language highlights the prevailing problem with investing in Amarin. Specifically, the lack of factual knowledge on what is really going on as respects the commercialization direction Amarin will take. Joe Z's style of management has led to endless speculation and subsequently the share price has suffered tremendously and along with it, shareholders. What little we have been given by management, i.e. buyout hopes have been dashed repeatedly.


    I realize this is all part of the game but Joe Z's MO has resulted in a lack of institutional support as well as retail support. My suggestion to you is to not fall into that trap yourself.
    If you know something that will help all of us, by all means share it. Otherwise it is better to refrain from comment. If a concrete plan for commercialization of the ANCHOR indication isn't in place shortly( or at least articulated) after approval of the ANCHOR sNDA, it will indicate to investors that management is struggling and adrift.
    9 Apr 2013, 07:35 PM Reply Like
  • onecardchuck
    , contributor
    Comments (36) | Send Message
    I 100% concur with chunk713 and he is now on ihub as well.
    9 Apr 2013, 07:36 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (765) | Send Message
    Author’s reply » If you look at my bio you will see something about Guidepoint Global, so read into that what you will...
    10 Apr 2013, 08:48 AM Reply Like
  • Pirateescapee
    , contributor
    Comments (111) | Send Message
    Steve - You have no idea how bad I want you to be correct! I am not only an investor but on Vascepa (off label). I have 10s of thousands of reasons why your PT of $32 look real nice from this vantage point. Keep up the good work. Best wishes...........
    10 Apr 2013, 10:55 AM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.